Risk-Benefit Assessment of Glatiramer Acetate in Multiple Sclerosis

ISSN： 0114-5916

Source： Drug Safety, Vol.24, Iss.13, 2001-01, pp. : 979-990

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Glatiramer acetate for the treatment of multiple sclerosis

By Wolinsky Jerry S

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 4, 2004-04 ,pp. : 875-891

Informa Healthcare

Access to resources Recommend Favorite

Glatiramer acetate in the treatment of multiple sclerosis

By Sela Michael Teitelbaum Dvora

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 7, 2001-07 ,pp. : 1149-1165

Informa Healthcare

Access to resources Recommend Favorite

The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment

By Messina Silvia Patti Francesco

Expert Opinion on Drug Metabolism and Toxicology, Vol. 9, Iss. 10, 2013-10 ,pp. : 1349-1359

Informa Healthcare

Access to resources Recommend Favorite

Glatiramer Acetate: A Review of its Use in Relapsing-Remitting Multiple Sclerosis

By Simpson D. Noble S. Perry C.

CNS Drugs, Vol. 16, Iss. 12, 2002-01 ,pp. : 825-850

Adis International

Access to resources Recommend Favorite

Benefit-risk assessment of interferon-b therapy for relapsing multiple sclerosis

By Francis Gordon

Expert Opinion on Drug Safety, Vol. 3, Iss. 4, 2004-07 ,pp. : 289-303

Informa Healthcare

Access to resources Recommend Favorite